TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07544589: A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Sponsor: Dispatch Biotherapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 66 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07544589 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07544589 Rescue Dossier →